List all clinical trials by discovery date. Accepts regular expressions in search.

GET /trials/
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 802,
    "next": "http://api.gregory-ms.com/trials/?page=2",
    "previous": null,
    "results": [
        {
            "trial_id": 458148,
            "title": "Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis",
            "summary": "<b>Conditions</b>:    Multiple Sclerosis;   Clinically Isolated Syndrome;   Relapsing Remitting Multiple Sclerosis;   Progressive Multiple Sclerosis<br /><b>Interventions</b>:    Diagnostic Test: Eye tracking;   Diagnostic Test: Microperimetry;   Diagnostic Test: Optical coherence tomography (OCT);   Diagnostic Test: Visual processing speed test<br /><b>Sponsors</b>:    Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Fundación Eugenio Rodríguez Pascual;   Hospital del Río Hortega<br /><b>Enrolling by invitation</b>",
            "published_date": "2023-01-31T12:00:00Z",
            "discovery_date": "2023-01-31T15:01:20.991586Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05706220?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 458146,
            "title": "Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)",
            "summary": "<b>Condition</b>:    Relapse Remitting Multiple Sclerosis<br /><b>Intervention</b>:    Other: Blood Draw<br /><b>Sponsor</b>:    Thomas Jefferson University<br /><b>Recruiting</b>",
            "published_date": "2023-01-31T12:00:00Z",
            "discovery_date": "2023-01-31T15:01:20.985511Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05705986?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 457773,
            "title": "A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: RO7121932<br /><b>Sponsor</b>:    Hoffmann-La Roche<br /><b>Recruiting</b>",
            "published_date": "2023-01-30T12:00:00Z",
            "discovery_date": "2023-01-30T14:42:42.738076Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05704361?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 456540,
            "title": "Understanding the &#39;Wearing Off&#39; Effect From Disease-modifying Therapies (DMT) in Patients With Multiple Sclerosis: an Interview Based Study Among Patients and Clinicians",
            "summary": null,
            "published_date": null,
            "discovery_date": "2023-01-27T16:47:09.042140Z",
            "link": "https://www.novartis.com//clinicaltrials/study/nct05627271",
            "source": "Novartis",
            "relevant": null
        },
        {
            "trial_id": 456472,
            "title": "A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Drug: Natalizumab<br /><b>Sponsor</b>:    Biogen<br /><b>Not yet recruiting</b>",
            "published_date": "2023-01-27T12:00:00Z",
            "discovery_date": "2023-01-27T14:10:49.062160Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05701423?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 455969,
            "title": "Multiple Sclerosis and Respiratory and Functional Capacity",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Other: Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test<br /><b>Sponsors</b>:    Nigde Omer Halisdemir University;   Pamukkale University<br /><b>Completed</b>",
            "published_date": "2023-01-26T12:00:00Z",
            "discovery_date": "2023-01-26T14:20:45.348870Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05697523?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 454477,
            "title": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...",
            "summary": "<p>EudraCT Number: 2010-020315-36<br />Sponsor Protocol Number: WA21093<br />Sponsor Name: F.Hoffmann-La Roche<br />Start Date: 2011-10-18<br />Medical condition: Relapsing Multiple Sclerosis<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SK\">SK</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BE\">BE</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/SE\">SE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/DE\">DE</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/ES\">ES</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/GB\">GB</a> (GB - no longer in EU/EEA), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/BG\">BG</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/FR\">FR</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IE\">IE</a> (Completed), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/IT\">IT</a> (Ongoing), <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-020315-36/CZ\">CZ</a> (Ongoing)</p>",
            "published_date": null,
            "discovery_date": "2023-01-23T13:40:48.110763Z",
            "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2010-020315-36",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 453260,
            "title": "A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)",
            "summary": null,
            "published_date": null,
            "discovery_date": "2023-01-20T09:47:09.794479Z",
            "link": "https://www.novartis.com//clinicaltrials/study/nct04486716",
            "source": "Novartis",
            "relevant": null
        },
        {
            "trial_id": 452970,
            "title": "Cognitive Reserve-building Activities in Multiple Sclerosis",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Intervention</b>:    Behavioral: Cognitive Leisure Activities<br /><b>Sponsors</b>:    Rigshospitalet, Denmark;   University of Copenhagen<br /><b>Recruiting</b>",
            "published_date": "2023-01-19T12:00:00Z",
            "discovery_date": "2023-01-19T13:40:49.701276Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05691192?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        },
        {
            "trial_id": 452592,
            "title": "A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate",
            "summary": "<b>Condition</b>:    Multiple Sclerosis<br /><b>Interventions</b>:    Drug: Diroximel Fumarate;   Biological: Alemtuzumab;   Drug: Fingolimod;   Drug: Glatiramer acetate;   Biological: Interferon beta;   Biological: Natalizumab;   Biological: Ocrelizumab;   Biological: Peginterferon beta-1a;   Drug: Siponimod<br /><b>Sponsor</b>:    Biogen<br /><b>Recruiting</b>",
            "published_date": "2023-01-18T12:00:00Z",
            "discovery_date": "2023-01-18T14:20:48.914198Z",
            "link": "https://clinicaltrials.gov/ct2/show/NCT05688436?cond=Multiple+Sclerosis&sfpd_d=14&sel_rss=new14",
            "source": null,
            "relevant": null
        }
    ]
}